medigraphic.com
ISSN 0185-3252 (Print)
Revista de la Asociación Médica del Centro Médico ABC

2003, Number 1

<< Back Next >>

An Med Asoc Med Hosp ABC 2003; 48 (1)

Antibiotic resistance, public health problem

Rivera-Tapia JA

Language: English
References: 50
Page: 42-47
PDF size: 61.53 Kb.


ABSTRACT

Antibiotic resistance has become a major clinical and public health problem within the lifetime of most people living today. Confronted by increasing amounts of antibiotics over the past 50 years, bacteria have responded to the deluge with the propagation of progeny no longer susceptible to them. While it is clear that antibiotics are pivotal in the selection of bacterial resistance, the spread of resistance genes and of resistant bacteria also contributes to the problem. Selection of resistant forms can occur during or after antimicrobial treatment, antibiotic residues can be found in the environment for long periods of time after treatment. Beside antibiotics, there is the mounting use of other agents aimed at destroying bacteria, namely the surface antibacterials now available in many household products. These too enter the environment. The stage is thus set for an altered microbial ecology, not only in terms of resistant versus susceptible bacteria, but also in terms of the kinds of microorganisms surviving.


REFERENCES

  1. Livermore DM. b-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995; 8: 557-584.

  2. Barriga AG, Rojas ML, Peredo LVM. Actualidades en los patrones de resistencia a los antimicrobianos. Rev Mex Patol Clin 2001; 48: 65-69.

  3. Chopra J, Hawkey PM, Hinton M. Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 1992; 29: 247-277.

  4. Tomasz A, Munoz R. b-lactam antibiotic resistance in Gram positive bacteria pathogens of the upper respiratory ttract: a brief overview of mechanisms. Microbiol Drug Resistance 1995; 1: 103-109.

  5. Garcia-Bustos J, Tomasz A. A biological price of antibiotic resistance: major changes in the peptidoglycan structure of penicillin-resistant pneumococci. Proc Natl Acad Sci USA 1990; 87: 5415-5419.

  6. Michel M, Gutmann L. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Lancet 1997; 349: 1901-1906.

  7. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997; 24: 545-556.

  8. Craig WA. Temas del futuro de la resistencia antimicrobiana. Enf Infec Micro 2000; 20: 172-177.

  9. Levy SB. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 2002; 49: 25-30.

  10. Cohen ML. Epidemiology of drugs resistance: implications for a post-antimicrobial era. Science 1992; 257: 1050-1055.

  11. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoine MH et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995; 274: 639-644.

  12. Vandenbroucke-Grauls C. Management of methicillin-resistant Staphylococcus aureus in the Netherlands. Rev Med Microbiol 1998; 9: 109-116.

  13. Mulligan ME, Murray-Leisure KA, Ribner BS, Standiford HC, John JF, Korvick JA et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis and epidemiology with implications for prevention and management. Am J Med 1993; 94: 313-328.

  14. Gold HS, Moellering RC. Antimicrobial-drug resistance. N Engl J Med 1996; 335: 1445-1453.

  15. Livermore DM, Yuan M. Antibiotic resistance and production of extended-sprectrum b-lactamases amongst Klebsiella spp from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-424.

  16. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Jonhson MP et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585-590.

  17. De Cheldre Y, Maes N, Rost F, De Ryck R,Clevenbergh P, Vincent JL et al. Molecular epidemiology of an outbreak of multidrug-resistant Enterobacter aerogenes infections and in vivo emergence of imipenem resistance. J Clin Microbiol 1997; 35: 152-160.

  18. Towner KJ. Clinical importance and antibiotic resistance of Acinetobacter spp. J Med Microbiol 1997; 46: 721-746.

  19. Struelens MJ, Carlier E, Maes N, Serruys E, Quint WGV, van Belkum A. Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: Outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. J Hosp Infect 1993; 25: 15-32.

  20. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. J Infect Dis 1983; 5: 1033-1048.

  21. Davies JE. Origins, acquisition and dissemination of antibiotic resistance determinants. Ciba Found Symp 1997; 207: 15-27.

  22. Fluit AdC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin Microbiol Rev 2001; 14: 836-871.

  23. Lederberg J, Lederberg EM. Replica plating and indirect selection of bacterial mutants. J Bacteriol 1952; 63: 399-406.

  24. Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 1943; 28: 491-511

  25. Hopper DC. Mechanisms of fluoroquinolone resistance. Drug Resis Updates 1999; 2: 38-55.

  26. Martinez JL, Alonso A, Gomez-Gomez JM, Baquero F. Quinolone resistance by mutations in chromosomal gyrase genes. Just the tip of the iceberg? J Antimicrob Chemother 1998; 42: 683-688.

  27. Figueiredo AM, Ha E, Kreiswirth BN, Lencastre de H, Noel GJ, Senterfit L, Tomasz A. In vitro stability of heterogeneous expression classes in clinical isolates of methicillin-resistant staphylococci. J Infect Dis 1991; 164: 883-887.

  28. Kohler T, Michea-Hamzehpour M, Plesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41: 2540-2543.

  29. Hughes D, Andersson DI. Carbon starvation of Salmonella typhimurium does not cause a general increase of mutation rates. J Bacteriol 1997; 179: 6688-6691.

  30. Foster PL. Adaptive mutation: the uses of adversity. Annu Rev Microbiol 1993; 47: 467-504.

  31. Shapiro JA. Genome organization, natural genetic engineering and adaptive mutation. Trends Genet 1997; 13: 98-104.

  32. LeClerc JE, Li B, Payne WL, Cebula TA. High mutation frequencies among Escherichia coli and Salmonella pathogens. Science 1996; 274: 1208-1211.

  33. Taddei F, Radman M, Maynard-Smith J, Toupance B, Gouyon PH, Godelle B. Role of mutator alleles in adaptative evolution. Nature 1997; 387: 700-702.

  34. Mamber SW, Kolek B, Brookshire KW, Bonner DP, Fung-Tomc J. Activity of quinolones in the Ames Salmonella TA102 mutagenicity test and other bacterial genotoxicity assays. Antimicrob Agents Chemother 1993; 37: 213-217.

  35. Ren L, Rahman MS, Humayun MZ. Escherichia coli cells exposed to streptomycin display a mutator phenotype. J Bacteriol 1999; 181: 1043-1044.

  36. Fish DN, Piscitelli SC, Danzinger LH. Development of resistance during antimicrobial therapy: A review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy 1995; 15: 279-291.

  37. Kristinsson KG, Hijalmarsdottir M, Steingrimsson O. Increasing penicillin resistance in pneumococci in Iceland. Lancet 1992; 399: 1606-1607.

  38. Ekdahl K, Cars O. Role of communicable disease control measures in affecting the spread of resistant pneumococci the Swedish model. Clin Microbiol Infect 1998; 5 (suppl 4): S48-54.

  39. Tomasz A. The challenge of multiresistant Streptococcus pneumoniae: international initiatives in day-care centers and the use of molecular epidemiologic techniques. Clin Microbiol Infect 1998; 5, (suppl 4): S64-68.

  40. Davies J. Inactivation of antibiotics and the dissemination of resistance genes. Science 1994; 264: 375-382.

  41. Houndt T, Ochman H. Long-term shifts in patterns of antibiotic resistance in enteric bacteria. Appl Envir Microbiol 2000; 66: 5406-5409.

  42. Grahn E, Holm SE. Penicillin concentration in saliva and its influence on bacterial interference. Scan J Infect Dis 1987; 19: 235-241.

  43. Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986; 49: 64-72.

  44. Spratt BG. Resistance to antibiotic mediated by target alterations. Science 1994; 264: 388-393.

  45. Edlund C, Nord CE. Ecological impact of antimicrobial agents on human intestinal microflora. Alpe Adria Microbiol J 1993; 3: 137-164.

  46. Hoiby N, Johansen HK. Ciprofloxacin in sweat and antibiotic resistance. The Copenhagen Study Group on Antibiotics in Sweat. Lancet 1995; 346: 1235.

  47. Hoiby N, Jarlov JO, Kemp M, Tvede M, Bangsborg JM, Kjerulf A et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349: 167-169.

  48. Gahm-Hansen B. Coagulase-negative staphylococci and micrococci in clinical microbiology. Danish Med Bulletin 1987; 34: 96-114.

  49. Jarlov JO, Hoiby N. Coagulase-negative staphylococci in a major Danish university hospital: diversity in antibiotic susceptibility between wards. Act Path Microbiol Immun Scan 1998; 106: 411-416.

  50. Rodríguez RS, Calderón JE, Gómez BD, Espinosa ML. Características de la resistencia antimicrobiana de una colección clínica de Streptococcus pyogenes. Sal Pub Mex 2000; 42: 226-229.




2020     |     www.medigraphic.com